SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Google

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Treatment hope for cognitive symptoms in Parkinson's disease
Tues May 17th - Ultra-powerful 7T MRI scanners could help to identify those patients with conditions such as Parkinson's disease who would benefit from new treatments for cognitive symptoms that were previously untreatable, British researchers report today. More
E-cigarettes as effective as patches for pregnant women
Tues May 17th - E-cigarettes can help pregnant women to stop smoking and are as safe as nicotine patches, according to new UK research. More
RECENT COMMENTS
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Preclinical trials provide hope for brain injury recovery

Tuesday February 25th, 2020

Resetting immune cells could help to treat people with traumatic brain injury, a new study has found.

The preclinical research in mice also established that the impact of TBI on brain degeneration may be modifiable sometime after the injury is sustained.

The findings from the collaborative research, involving scientists from Trinity College Dublin and the University of Maryland School of Medicine, Baltimore, USA, are published today (24 February 2020) in the Journal of Neuroscience.

When triggered by trauma, microglia morph into an inflammatory state, which helps to protect the brain.

However, long-term inflammation after TBI can contribute to neurological degeneration and cognitive declines, similar to those observed in TBI-associated neurodegenerative diseases.

In this study, the research team found suppressing chronic inflammation, even months after the injury, could provide a new treatment for TBI.

One month after a TBI, the team inhibited a receptor that microglia need to survive, which killed 95% of the mice microglia cells. However, the cells bounced back to normal levels once the inhibition ended.

The inhibition was stopped after one week and the mice were allowed to recover for a few months. The researchers then discovered that the inhibition “reset” the mice's microglia and the new cells were in a more normal, less inflammatory state.

Those mice recovered better than the mice that did not receive treatment, and also demonstrated less brain damage, fewer neuron deaths, and better motor and cognitive performance.

Dr David Loane, research assistant professor in Trinity's School of Biochemistry and Immunology, said: "These preclinical studies suggest that the consequences of TBI on brain degeneration and related neurological impairment may be modifiable quite a long time after injury by targeting inflammation pathways, which is a finding at odds with widely accepted views about head injury.

"The exciting thing is the possibility that we may one day be able to minimise brain degeneration and neurological impairment in people who have suffered a TBI. It will of course always be incredibly important to act quickly whenever someone suffers a TBI, but our findings suggest targeting inflammation pathways further down the treatment line may make a major difference to long-term brain health and recovery."

Henry et al. Microglial Depletion With CSF1R Inhibitor During Chronic Phase of Experimental Traumatic Brain Injury Reduces Neurodegeneration and Neurological Deficits. Journal of Neuroscience 24 February 2020.

http://dx.doi.org/10.1523/JNEUROSCI.2402-19.2020

Tags: A&E | Brain & Neurology | Europe | North America

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES